Shea-Donohue Terez, Fasano Alessio, Zhao Aiping, Notari Luigi, Yan Shu, Sun Rex, Bohl Jennifer A, Desai Neemesh, Tudor Greg, Morimoto Motoko, Booth Catherine, Bennett Alexander, Farese Ann M, MacVittie Thomas J
a Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland;
b Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland;
Radiat Res. 2016 Jun;185(6):591-603. doi: 10.1667/RR14024.1. Epub 2016 May 25.
In this study, nonhuman primates (NHPs) exposed to lethal doses of total body irradiation (TBI) within the gastrointestinal (GI) acute radiation syndrome range, sparing ∼5% of bone marrow (TBI-BM5), were used to evaluate the mechanisms involved in development of the chronic GI syndrome. TBI increased mucosal permeability in the jejunum (12-14 Gy) and proximal colon (13-14 Gy). TBI-BM5 also impaired mucosal barrier function at doses ranging from 10-12.5 Gy in both small intestine and colon. Timed necropsies of NHPs at 6-180 days after 10 Gy TBI-BM5 showed that changes in small intestine preceded those in the colon. Chronic GI syndrome in NHPs is characterized by continued weight loss and intermittent GI syndrome symptoms. There was a long-lasting decrease in jejunal glucose absorption coincident with reduced expression of the sodium-linked glucose transporter. The small intestine and colon showed a modest upregulation of several different pro-inflammatory mediators such as NOS-2. The persistent inflammation in the post-TBI-BM5 period was associated with a long-lasting impairment of mucosal restitution and a reduced expression of intestinal and serum levels of alkaline phosphatase (ALP). Mucosal healing in the postirradiation period is dependent on sparing of stem cell crypts and maturation of crypt cells into appropriate phenotypes. At 30 days after 10 Gy TBI-BM5, there was a significant downregulation in the gene and protein expression of the stem cell marker Lgr5 but no change in the gene expression of enterocyte or enteroendocrine lineage markers. These data indicate that even a threshold dose of 10 Gy TBI-BM5 induces a persistent impairment of both mucosal barrier function and restitution in the GI tract and that ALP may serve as a biomarker for these events. These findings have important therapeutic implications for the design of medical countermeasures.
在本研究中,将处于胃肠道(GI)急性放射综合征范围内接受致死剂量全身照射(TBI)且约5%的骨髓得以保留(TBI-BM5)的非人灵长类动物(NHPs)用于评估慢性胃肠综合征发生发展所涉及的机制。TBI使空肠(12 - 14 Gy)和近端结肠(13 - 14 Gy)的黏膜通透性增加。TBI-BM5在小肠和结肠中剂量为10 - 12.5 Gy时也会损害黏膜屏障功能。对接受10 Gy TBI-BM5照射后6 - 180天的NHPs进行定时尸检显示,小肠的变化先于结肠。NHPs的慢性胃肠综合征的特征是持续体重减轻和间歇性胃肠综合征症状。空肠葡萄糖吸收长期下降,同时钠联葡萄糖转运体表达降低。小肠和结肠显示出几种不同促炎介质如NOS-2的适度上调。TBI-BM5后时期的持续炎症与黏膜修复的长期受损以及肠和血清碱性磷酸酶(ALP)水平表达降低有关。照射后时期的黏膜愈合依赖于干细胞隐窝的保留以及隐窝细胞成熟为适当的表型。在10 Gy TBI-BM5照射后30天,干细胞标志物Lgr5的基因和蛋白表达显著下调,但肠上皮细胞或肠内分泌谱系标志物的基因表达没有变化。这些数据表明,即使是10 Gy TBI-BM5的阈值剂量也会导致胃肠道黏膜屏障功能和修复的持续受损,并且ALP可能作为这些事件的生物标志物。这些发现对医学对策的设计具有重要的治疗意义。